Why Edgewise Therapeutics Stock Rocked the Market Today The company just might have a winner on its hands with a pipeline heart disease treatment.
Let's take a look at the stocks that are in motion in today's session. Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results December 3, 2025 – Capricor Therapeutics (
NASDAQ: CAPR ) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an eight-year high. The dramatic ascent follows the announcement of overwhelmingly positive top-line results from its pivotal Phase 3 HOPE-3 study for
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.
Edgewise Therapeutics Inc (NASDAQ:EWTX) Q2 2025 Earnings: EPS Beat Sparks 5% Pre-Market Rally Edgewise Therapeutics (EWTX) reports Q2 2025 EPS beat at -$0.34 vs. -$0.42 estimates, sparking a 5% pre-market rally. Clinical progress in muscle disease treatments drives optimism.
No Accelerated FDA Approval For Edgewise's Rare Muscular Disease Drug; Shares Fall Edgewise reports sustained functional stability in Becker patients and selects Phase 3 dose for Duchenne after positive Phase 2 trial data.
Top movers in Friday's after hours session As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Top movers in Wednesday's session Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
These stocks are moving in today's session Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
Traders are paying attention to the gapping stocks in Wednesday's session. In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.
Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study Edgewise's EDG-7500 lowered LVOT gradient and NT-proBNP levels in HCM patients, improving symptoms. Initial Part D data is expected in late 2025.
These stocks are moving in today's pre-market session The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Why Edgewise Therapeutics (EWTX) Stock Is Falling Edgewise Therapeutics shares are trading lower by 25.7% during Wednesday's session. The company announced an approximate $200 million offering.
Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged Edgewise Therapeutics stock dropped, as Cytokinetics shares got a big boost early Wednesday.
